Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Ophthalmol ; 153(2): 327-333.e1, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21930258

ABSTRACT

PURPOSE: To determine the serum concentrations of bevacizumab and vascular endothelial growth factor (VEGF) in infants with retinopathy of prematurity (ROP) who received intravitreal bevacizumab; and to determine whether the changes in the serum concentration of bevacizumab were significantly correlated with the serum concentration of VEGF after intravitreal bevacizumab. DESIGN: Case series. METHODS: Eleven infants (4 girls and 7 boys) with ROP were studied. They received 0.25 mg or 0.5 mg of intravitreal bevacizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases) with vascularly active ROP. Serum samples were collected before and 1 day, 1 week, and 2 weeks after the intravitreal bevacizumab. The serum concentrations of bevacizumab and VEGF were measured by enzyme-linked immunosorbent assay, and the correlation in the serum levels between the 2 was determined. RESULTS: The serum concentration of bevacizumab before and 1 day, 1week, and 2 weeks after a total of 0.5 mg of intravitreal bevacizumab was 0 ng/mL, 195 ± 324 ng/mL, 946 ± 680 ng/mL, and 1214 ± 351 ng/mL, respectively. The serum bevacizumab level before and 1 day and 1 week after a total 1.0 mg of intravitreal bevacizumab was 0 ng/mL, 248 ± 174 ng/mL, and 548 ± 89 ng/mL, respectively. The serum concentration of VEGF before and 1 day, 1 week, and 2 weeks after a total of 0.5 mg intravitreal bevacizumab was 1628 ± 929 pg/mL, 427 ± 140 pg/mL, 246 ± 110 pg/mL, and 269 ± 157 pg/mL, respectively. There was a significant negative correlation (r = -0.575, P = .0125) between the serum concentration of bevacizumab and VEGF when a total of 0.25 mg or 0.5 mg of bevacizumab was injected. CONCLUSIONS: These results indicate that bevacizumab can escape from the eye into the systemic circulation and reduce the serum level of VEGF in infants with ROP. Continued extensive evaluations of infants are warranted for possible effects after intravitreal bevacizumab in ROP patients.


Subject(s)
Angiogenesis Inhibitors/pharmacokinetics , Antibodies, Monoclonal, Humanized/pharmacokinetics , Retinopathy of Prematurity/metabolism , Vascular Endothelial Growth Factor A/blood , Bevacizumab , Biological Availability , Enzyme-Linked Immunosorbent Assay , Female , Gestational Age , Humans , Infant, Extremely Low Birth Weight , Infant, Newborn , Intravitreal Injections , Laser Coagulation , Male , Retinopathy of Prematurity/surgery , Vascular Endothelial Growth Factor A/antagonists & inhibitors
2.
Int Arch Allergy Immunol ; 137(2): 115-24, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15855793

ABSTRACT

BACKGROUND: A toluene-2,4-diisocyanate (TDI)-induced asthma model, in which delayed-type hypersensitivity-like asthmatic airway obstruction is elicited restrictively in the lung, has never been developed. METHODS: Guinea pigs were percutaneously sensitized with TDI. For the challenges, once every 2 weeks for a total of 5 times, TDI mists were delivered directly to the lung through an oral cannula, with its tip being positioned in the opening of the trachea. Time-course changes in specific airway resistance (sRaw) were measured by double-flow plethysmography. Basic mechanisms underlying TDI-induced asthma were analyzed. RESULTS: After the 2nd-5th challenges, induction of both an early increase in sRaw that peaked at 10 min and a delayed-type sRaw elevation that peaked at 22 h were observed. Interestingly, in the sensitized/challenged animals, baseline sRaw was elevated by repeated challenge as compared to that seen for non-sensitized animals. Intratracheal administration of a bronchodilator, salbutamol, strongly suppressed the early asthmatic response (EAR) but not the delayed-type asthmatic response (DAR). During DAR, both albumin leakage and fucose secretion into the bronchoalveolar lavage fluid were increased. The cysteinyl leukotriene antagonist pranlukast failed to inhibit either EAR or DAR while the corticosteroid dexamethasone significantly suppressed DAR, without significantly affecting EAR. CONCLUSIONS: Effective delivery of TDI to the lung may induce reproducible DAR in sensitized guinea pigs with chronicity that is reflected by an increase in the sRaw baseline. DAR is not mediated by constriction of airway smooth muscles and is probably due to the concurrent presence of mucosal edema and mucus hypersecretion in the airways.


Subject(s)
Asthma/chemically induced , Disease Models, Animal , Guinea Pigs , Hypersensitivity, Delayed/chemically induced , Toluene 2,4-Diisocyanate/toxicity , Airway Resistance , Albumins/metabolism , Albuterol/pharmacology , Allergens/immunology , Allergens/toxicity , Animals , Asthma/immunology , Chromones/pharmacology , Dexamethasone/pharmacology , Fucose/metabolism , Hypersensitivity, Delayed/immunology , Immunoglobulin E/metabolism , Immunoglobulin G/metabolism , Male , Time Factors , Toluene 2,4-Diisocyanate/immunology , Trachea
3.
J Pharmacol Sci ; 95(4): 435-42, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15286429

ABSTRACT

Platelet-activating factor (PAF) plays important roles in allergic reactions. In particular, there are many concerns about PAF, eosinophils, and the chronicity of allergic diseases. The purpose of the present studies is to elucidate the role of PAF in eosinophil activation at conjunctiva and to confirm the efficacy of Apafant (a potent PAF antagonist) ophthalmic solution in chronic experimental allergic conjunctivitis. Guinea pigs were actively immunized and allergic conjunctivitis was induced by repetitive instillation of 2.5% ovalbumin. PAF solution was topically applied and eosinophil activation was assessed by measuring the eosinophil peroxidase (EPO) activity in the tear fluid. Itch-scratching episodes and clinical symptoms scores were evaluated in the repetitive challenge conjunctivitis. From the instillation of PAF solution into guinea pig eyes, which were in a state of chronic allergic conjunctivitis, a significant increase in EPO activity was observed, and this increase was inhibited by pre-treatment with Apafant. In the repetitive challenge model, the animals treated with Apafant ophthalmic solution showed a significant reduction of clinical symptoms and the itch-scratch response in both the first and the second challenges. PAF has an activity, that induces mediator release from eosinophils in the conjunctival tissues and may be involved in the chronic phase of allergic conjunctivitis.


Subject(s)
Azepines/pharmacology , Conjunctivitis, Allergic/drug therapy , Eosinophils/drug effects , Platelet Activating Factor/antagonists & inhibitors , Triazoles/pharmacology , Administration, Topical , Animals , Azepines/therapeutic use , Chronic Disease , Conjunctiva/drug effects , Conjunctiva/immunology , Conjunctivitis, Allergic/immunology , Dose-Response Relationship, Drug , Eosinophil Peroxidase/metabolism , Eosinophils/enzymology , Eosinophils/immunology , Guinea Pigs , Male , Ophthalmic Solutions , Ovalbumin , Tears/enzymology , Triazoles/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...